Literature DB >> 10052476

Effect of renal dialysis therapy modality on T cell cytokine production.

A Zamauskaite1, I Perez-Cruz, M M Yaqoob, J A Madrigal, S B Cohen.   

Abstract

INTRODUCTION: Dialysis has been associated with acute changes in the complement activation status, granulocyte markers, macrophage function, T cell activation and the release of pro-inflammatory cytokines. The most common analysis of cytokine production in patients on dialysis has focused on the changes in monokines (particularly IL-1 and TNF alpha), however it is becoming clear that T cell cytokines play a major role in the impaired lymphocyte function of dialysis patients.
METHODS: To assess the effect of dialysis modality on T cell function we analysed the ability of T cells within peripheral blood mononuclear cell populations (PBMC) to produce cytokines after mitogen (phorbol-12-myristate-13-acetate; PMA and lonomycin; I) stimulation in patients on peritoneal dialysis (PD) compared to low flux haemodialysis (HD) and normal individuals (controls).
RESULTS: In control PBMC, PMA + I stimulation significantly increased the percentage of CD3+ cells expressing IL-2, IFN gamma, TNF alpha, IL-4 and IL-10, as expected. However, although mitogen stimulation significantly enhanced the percentage of the classical Th1 cytokines (IL-2, IFN gamma and TNF alpha) in the low flux HD PBMC, it had no effect on CD3+ IL-2 or CD3+ TNF alpha producing cells in the PD group. In contrast, the percentage of T cells producing Th2 cytokines (IL-4 and IL-10) could not be consistently enhanced by mitogen in either dialysis group.
CONCLUSIONS: We suggest that PD alters the ability of T cells to produce cytokines, possibly by causing an 'exhaustion' of the Th1 cells, thereby preventing cells to produce cytokine on ex vivo stimulation. Furthermore, since T cells from both low flux HD and PD groups could not be induced to produce Th2 cytokines we suggest that uraemia or dialysis per se inhibits T cells from producing Th2 cytokines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052476     DOI: 10.1093/ndt/14.1.49

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis.

Authors:  H J Ankersmit; R Deicher; B Moser; I Teufel; G Roth; S Gerlitz; S Itescu; E Wolner; G Boltz-Nitulescu; J Kovarik
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

2.  Children with chronic renal failure have reduced numbers of memory B cells.

Authors:  A H M Bouts; J C Davin; R T Krediet; L A H Monnens; J Nauta; C H Schröder; R A W van Lier; T A Out
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

3.  Serial interferon-gamma release assays for latent tuberculosis in dialysis patients with end stage renal disease in a Korean population.

Authors:  Seung Heon Lee; Hee Jin Kim; Seok Ju Park; Tae Hee Kim; So Jeong Park; Sun Woo Kang; Yeong Hoon Kim; Dick Menzies
Journal:  BMC Infect Dis       Date:  2015-09-21       Impact factor: 3.090

4.  Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production.

Authors:  Guadalupe T González-Mateo; Vanessa Fernández-Míllara; Teresa Bellón; Georgios Liappas; Marta Ruiz-Ortega; Manuel López-Cabrera; Rafael Selgas; Luiz S Aroeira
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

5.  Circulating chemokine ligand levels before and after successful kidney transplantation.

Authors:  Hamdi Elmoselhi; Holly Mansell; Mahmoud Soliman; Ahmed Shoker
Journal:  J Inflamm (Lond)       Date:  2016-10-26       Impact factor: 4.981

6.  Acute effect of hemodialysis on serum levels of the proinflammatory cytokines.

Authors:  Mehmet Tarakçioğlu; Ayşe Binnur Erbağci; Celalettin Usalan; Rukiye Deveci; Ramazan Kocabaş
Journal:  Mediators Inflamm       Date:  2003-02       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.